S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.40 (+0.11%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   353.15 (+2.08%)
GOOGL   2,845.99 (+0.77%)
TSLA   774.39 (+2.75%)
AMZN   3,425.26 (+0.27%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.02 (-0.03%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.40 (+0.11%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   353.15 (+2.08%)
GOOGL   2,845.99 (+0.77%)
TSLA   774.39 (+2.75%)
AMZN   3,425.26 (+0.27%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.02 (-0.03%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.40 (+0.11%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   353.15 (+2.08%)
GOOGL   2,845.99 (+0.77%)
TSLA   774.39 (+2.75%)
AMZN   3,425.26 (+0.27%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.02 (-0.03%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.40 (+0.11%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   353.15 (+2.08%)
GOOGL   2,845.99 (+0.77%)
TSLA   774.39 (+2.75%)
AMZN   3,425.26 (+0.27%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.02 (-0.03%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
NASDAQ:MDWD

MediWound Stock Forecast, Price & News

$3.49
+0.03 (+0.87 %)
(As of 09/24/2021 04:05 PM ET)
Add
Compare
Today's Range
$3.44
$3.54
50-Day Range
$3.41
$4.63
52-Week Range
$3.10
$6.22
Volume54,472 shs
Average Volume238,666 shs
Market Capitalization$95.06 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54
30 days | 90 days | 365 days | Advanced Chart
Receive MDWD News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.


MediWound logo

About MediWound

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

822nd out of 1,351 stocks

Medicinals & Botanicals Industry

6th out of 18 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











MediWound (NASDAQ:MDWD) Frequently Asked Questions

Is MediWound a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MediWound stock.
View analyst ratings for MediWound
or view top-rated stocks.

What stocks does MarketBeat like better than MediWound?

Wall Street analysts have given MediWound a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MediWound wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MediWound's next earnings date?

MediWound is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for MediWound
.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) posted its quarterly earnings results on Tuesday, August, 10th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.01. MediWound had a negative net margin of 38.43% and a negative trailing twelve-month return on equity of 171.14%.
View MediWound's earnings history
.

How has MediWound's stock been impacted by COVID-19 (Coronavirus)?

MediWound's stock was trading at $2.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MDWD shares have increased by 51.1% and is now trading at $3.49.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MDWD?

3 analysts have issued twelve-month price objectives for MediWound's shares. Their forecasts range from $6.50 to $9.00. On average, they expect MediWound's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 114.9% from the stock's current price.
View analysts' price targets for MediWound
or view top-rated stocks among Wall Street analysts.

Who are MediWound's key executives?

MediWound's management team includes the following people:
  • Sharon Malka, Chief Executive Officer
  • Boaz Gur-Lavie, Chief Financial Officer
  • Lior Rosenberg, Chief Medical Officer
  • Ety Klinger, Chief Research & Development Officer
  • Roni Solomon, Vice President-Finance

What other stocks do shareholders of MediWound own?

What is MediWound's stock symbol?

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

Who are MediWound's major shareholders?

MediWound's stock is owned by many different retail and institutional investors. Top institutional shareholders include Migdal Insurance & Financial Holdings Ltd. (4.39%), Renaissance Technologies LLC (1.74%), Sargent Investment Group LLC (1.23%), Morgan Stanley (0.28%), Morgan Stanley (0.28%) and JPMorgan Chase & Co. (0.24%).

Which major investors are selling MediWound stock?

MDWD stock was sold by a variety of institutional investors in the last quarter, including Migdal Insurance & Financial Holdings Ltd., Renaissance Technologies LLC, Sargent Investment Group LLC, and Creative Planning.

Which major investors are buying MediWound stock?

MDWD stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., Meitav Dash Investments Ltd., Meitav Dash Investments Ltd., Toroso Investments LLC, Squarepoint Ops LLC, and PDT Partners LLC.

How do I buy shares of MediWound?

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediWound's stock price today?

One share of MDWD stock can currently be purchased for approximately $3.49.

How much money does MediWound make?

MediWound has a market capitalization of $95.06 million and generates $21.76 million in revenue each year. The biopharmaceutical company earns $-9,200,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does MediWound have?

MediWound employs 75 workers across the globe.

What is MediWound's official website?

The official website for MediWound is www.mediwound.com.

Where are MediWound's headquarters?

MediWound is headquartered at 42 HAYARKON STREET, YAVNE L3, 8122745.

How can I contact MediWound?

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972779714100 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.